Emerg Infect Dis. 2020 Mar;26(3):541-548. doi: 10.3201/eid2603.191018. Epub 2020 Mar 17.
Little information exists regarding Ebola vaccine rVSVΔG-ZEBOV-GP and pregnancy. The Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE) randomized participants without blinding to immediate or deferred (18-24 weeks postenrollment) vaccination. Pregnancy was an exclusion criterion, but 84 women were inadvertently vaccinated in early pregnancy or became pregnant <60 days after vaccination or enrollment. Among immediate vaccinated women, 45% (14/31) reported pregnancy loss, compared with 33% (11/33) of unvaccinated women with contemporaneous pregnancies (relative risk 1.35, 95% CI 0.73-2.52). Pregnancy loss was similar among women with higher risk for vaccine viremia (conception before or <14 days after vaccination) (44% [4/9]) and women with lower risk (conception >15 days after vaccination) (45% [10/22]). No congenital anomalies were detected among 44 live-born infants examined. These data highlight the need for Ebola vaccination decisions to balance the possible risk for an adverse pregnancy outcome with the risk for Ebola exposure.
关于埃博拉疫苗 rVSVΔG-ZEBOV-GP 和妊娠，相关信息有限。塞拉利昂引入埃博拉疫苗试验（STRIVE）将参与者随机分为立即接种组和延迟接种组（接种后 18-24 周），但未设盲。妊娠是排除标准，但有 84 名女性在早期妊娠期间意外接种疫苗或在接种或登记后 <60 天怀孕。在立即接种疫苗的女性中，45%（14/31）报告流产，而同期妊娠的未接种疫苗女性中为 33%（11/33）（相对风险 1.35，95%CI 0.73-2.52）。对于疫苗病毒血症风险较高（接种前或接种后 <14 天受孕）的女性（44%[4/9]）和风险较低（接种后 >15 天受孕）的女性（45%[10/22]），流产率相似。对 44 名活产婴儿进行了检查，未发现先天性异常。这些数据突出表明，在权衡接种埃博拉疫苗的潜在不良妊娠结局风险与感染埃博拉风险时，应做出疫苗接种决策。
